Two More Drugs May Be Part of Fungal Meningitis Outbreak: FDA

Federal health experts are warning about the potential risk of contamination with two other drugs distributed by the compounding pharmacy at the center of a recent fungal meningitis outbreak, which has killed at least 15 people and sickened more than 200 others throughout the United States. 

The FDA issued a warning on October 15, indicating that patients who have been given the injectable steroid triamcinolone acetonide or who received cardioplegic solution during surgery should also be notified to see their doctor to ensure they do not have fungal meningitis.

The agency believes that vials of the two drugs that were distributed by New England Compounding Center (NECC) may also be contaminated.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Until now, investigators believed the outbreak to be restricted to the epidural steroid injection methylprednisolone acetate, which was recalled in early October.

The FDA says that cases of possible fungal meningitis have also been identified among users of the other two NECC drugs. Triamcinolone acetonide is another injection steroid product, and cardioplegic solution is used to paralyze the heart during heart surgery to prevent injury. The cases are still under investigation.

Although the focus of the outbreak was on the epidural steroid injections, NECC recalled all drugs mixed by the pharmacy on October 6, just two days after recalling the epidural steroid injection recall. The company has previously indicated that there are no problems with other drugs, but removed all of their products from the market amid the investigation.

The compounding pharmacy shut down as the scope of the investigation widened and after the FDA found 50 sealed vials at the facility that were contaminated. Earlier this week, Tennessee revoked the company’s license to work in that state.

Tennessee has been hardest hit by the outbreak, with six deaths and 53 illnesses. Michigan is a close second with three deaths and 46 sick. So far, 15 states have reported illnesses. In addition to Tennessee and Michigan, there have also been fungal meningitis infections reported in Florida, Idaho, Illinois, Indiana, Maryland, Minnesota, New Hampshire, New Jersey, North Carolina, Ohio, Pennsylvania, Texas and Virginia.

Before the FDA announced two new drugs possibly being linked to the outbreak, the U.S. Centers for Disease Control and Prevention (CDC) estimated that 14,000 people had been exposed to the drugs via epidural steroid injections. It is unclear how the addition of more suspect drugs will increase that number.

The first known first fungal meningitis outbreak lawsuit was filed late last week, by a Minnesota woman who is seeking class action status for everyone who potentially received tainted injections in that state. She has shown symptoms of fungal meningitis, but is awaiting lab test confirmation.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Depo-Provera Brain Tumor Warnings Added to Drug Label in Europe, But Not In U.S.
Depo-Provera Brain Tumor Warnings Added to Drug Label in Europe, But Not In U.S. (Posted yesterday)

A recently filed Depo-Provera lawsuit questions why Pfizer updated the drug label in Europe, to warn about the risk of meningioma brain tumors, but failed to provide the same Depo-Provera warnings to U.S. consumers and doctors.

Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week
Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week (Posted 3 days ago)

U.S. District Judge presiding over all federal hair relaxer lawsuits will meet with lawyers involved in the litigation on Thursday, to discuss the status of the claims and when to move forward with bellwether cases.